Current Report Filing (8-k)
May 13 2022 - 8:01AM
Edgar (US Regulatory)
0001497504
false
0001497504
2022-05-13
2022-05-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of report (Date of earliest event reported):
May 13, 2022
PLx Pharma Inc. |
(Exact Name of Registrant as Specified in Its Charter) |
Delaware |
|
001-36351 |
|
46-4995704 |
(State or other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
9 Fishers Lane, Suite E, Sparta, New Jersey |
|
07871 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (973) 409-6541
|
(Former name or former address if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the follow provisions:
☐ Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class |
Trading Symbol |
Name of each exchange on which registered |
Common Stock, $0.001 par value |
PLXP |
The NASDAQ Capital Market |
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company ☐
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 | Results of Operations and Financial Condition. |
On May 13, 2022, PLx Pharma Inc. (the “Company”)
issued a press release announcing its financial results for its first quarter ended March 31, 2022. The Company’s press release
is attached hereto as Exhibit 99.1 and the information set forth therein is incorporated herein by reference and constitutes a part of
this report.
The information furnished by the Company pursuant
to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liability of that section, and shall not be deemed
to be incorporated by reference into any Company filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless
of any general incorporation language in such filing.
| Item 9.01 | Financial Statements and Exhibits. |
(d) |
Exhibits |
|
|
|
|
|
Exhibit No. |
Description |
|
|
|
|
99.1 |
Press Release, dated May 13, 2022. |
|
|
|
|
104 |
Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
PLX PHARMA INC. |
|
|
|
|
|
|
|
|
|
Dated: May 13, 2022 |
By: |
/s/ Natasha Giordano |
|
|
|
Name: |
Natasha Giordano |
|
|
|
Title: |
President and Chief Executive Officer |
|
EXHIBIT INDEX
|
Exhibit No. |
Description |
|
|
|
|
99.1 |
Press Release, dated May 13, 2022. |
|
|
|
|
104 |
Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document). |
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Aug 2024 to Sep 2024
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Sep 2023 to Sep 2024